FWIW, this also ties in almost perfectly with the 2400 patient years for dosed patients, as implied by the study that was published sometime back.  The study had claimed 2700 patient years dosed on Apabetalone; Bear had estimated 300 patient years from Phase 2...which leaves 2400 patient years from Phase 3.

Remember, the more the patient years, the more time for the placebo group to accrue MACE events.  That means the less the number of patients on dosed who get MACE, with a fixed # of MACE events for Phase 3.  The only trouble is now the # of MACE events has gone up from 250 to 275.  So it all comes down to what the MACE rate for placebo patients turned out to be.  Anything equal or above 7, and we are a hit!